BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mgaieth S, Kemp W, Gow P, Fink M, Lubel J, Nicoll A, Gazzola A, Hong T, Ryan M, Knight V, Dev AT, Sood S, Bell S, Paul E, Roberts SK. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study. J Viral Hepat 2017;24:982-9. [PMID: 28414893 DOI: 10.1111/jvh.12717] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Huang YT. Causal mediation of semicompeting risks. Biometrics 2021. [PMID: 34195991 DOI: 10.1111/biom.13525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tajiri K, Kawai K, Sugiyama T. Reply to "Letter to Editor submitted by Rui Huang et al. entitled potential clinical application of strain elastography in chronic liver diseases". J Gastroenterol 2018;53:797-8. [PMID: 29623438 DOI: 10.1007/s00535-018-1461-3] [Reference Citation Analysis]
3 Lin J, Zhang H, Yu H, Bi X, Zhang W, Yin J, Zhao P, Liang X, Qu C, Wang M, Hu M, Liu K, Wang Y, Zhou Z, Wang J, Tan X, Liu W, Shao Z, Cai J, Tang W, Cao G. Epidemiological Characteristics of Primary Liver Cancer in Mainland China From 2003 to 2020: A Representative Multicenter Study. Front Oncol 2022;12:906778. [DOI: 10.3389/fonc.2022.906778] [Reference Citation Analysis]
4 Liu X, Qin S. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist 2019;24:S3-S10. [PMID: 30819826 DOI: 10.1634/theoncologist.2019-IO-S1-s01] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
5 Shen J, Liu J, Li C, Wen T, Yan L, Yang J. The Impact of Tumor Differentiation on the Prognosis of HBV-Associated Solitary Hepatocellular Carcinoma Following Hepatectomy: A Propensity Score Matching Analysis. Dig Dis Sci 2018;63:1962-9. [PMID: 29736828 DOI: 10.1007/s10620-018-5077-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
6 Yang F, Ma L, Yang Y, Liu W, Zhao J, Chen X, Wang M, Zhang H, Cheng S, Shen F, Wang H, Zhou W, Cao G. Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. Front Oncol 2019;9:370. [PMID: 31179237 DOI: 10.3389/fonc.2019.00370] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
7 Wei T, Zhang XF, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Pawlik TM. Long-term outcomes after curative resection of HCV-positive versus non-hepatitis related hepatocellular carcinoma: an international multi-institutional analysis. HPB (Oxford) 2020;22:1549-56. [PMID: 31987739 DOI: 10.1016/j.hpb.2020.01.003] [Reference Citation Analysis]
8 Wang L, Min Z, Wang X, Hu M, Song D, Ren Z, Cheng Y, Wang Y. Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand. Oncol Lett 2018;16:3341-50. [PMID: 30127933 DOI: 10.3892/ol.2018.8981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tan NP, Majeed A, Roberts SK, Gow PJ, Hey P, Mah X, Goodwin M, Sood S, Lubel J, Nicoll A, Dev A, Bell SJ, Kemp WW. Survival of patients with ruptured and non-ruptured hepatocellular carcinoma. Med J Aust 2020;212:277-8. [PMID: 31981417 DOI: 10.5694/mja2.50483] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ali R, Yang Y, Antkowiak M, Gabr A, Mora R, Abouchaleh N, Al Asadi A, Kulik L, Ganger D, Abecassis M, Kataraya N, Mulcahy M, Benson A, Mahalingam D, Thornburg B, Mouli S, Lewandowski RJ, Salem R, Riaz A. Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. Cardiovasc Intervent Radiol 2019;42:700-11. [DOI: 10.1007/s00270-019-02191-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Riaz A, Lewandowski R, Salem R. Radioembolization in Advanced Hepatocellular Carcinoma. J Clin Oncol 2018;36:1898-901. [PMID: 29718791 DOI: 10.1200/JCO.2018.77.7227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Mishra G, Dev A, Paul E, Cheung W, Koukounaras J, Jhamb A, Marginson B, Lim BG, Simkin P, Borsaru A, Burnes J, Goodwin M, Ramachandra V, Spanger M, Lubel J, Gow P, Sood S, Thompson A, Ryan M, Nicoll A, Bell S, Majeed A, Kemp W, Roberts SK; Melbourne Liver Group. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer 2020;20:483. [PMID: 32471447 DOI: 10.1186/s12885-020-06806-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Roberts SK, Gazzola A, Lubel J, Gow P, Bell S, Nicoll A, Dev A, Fink MA, Sood S, Knight V, Hong T, Paul E, Mishra G, Majeed A, Kemp W; Melbourne Liver Group. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. Scand J Gastroenterol 2018;53:1368-75. [PMID: 30394145 DOI: 10.1080/00365521.2018.1517277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]